The multiple facets of ovarian high grade serous carcinoma: A review on morphological, immunohistochemical and molecular features

被引:0
作者
Santoro, Angela [1 ,2 ]
Angelico, Giuseppe [3 ]
Travaglino, Antonio [4 ]
Inzani, Frediano [5 ,6 ]
Spadola, Saveria [3 ]
Pettinato, Angela [7 ]
Mazzucchelli, Manuel [8 ]
Bragantini, Emma [9 ]
Maccio, Livia [9 ]
Zannoni, Gian Franco [1 ,2 ]
机构
[1] Univ Cattolica Sacro Cuore, Pathol Inst, I-00168 Rome, Italy
[2] Fdn Policlin Univ Agostino Gemelli IRCCS, Dept Woman & Childs Hlth & Publ Hlth Sci, Pathol Unit, I-00168 Rome, Italy
[3] Kore Univ Enna, Dept Med & Surg, I-94100 Enna, Italy
[4] Univ Insubria, Dept Med & Technol Innovat, Pathol Unit, Varese, Italy
[5] Univ Pavia, Dept Mol Med, Anat Pathol Unit, I-27100 Pavia, Italy
[6] Fdn IRCCS San Matteo Hosp, I-27100 Pavia, Italy
[7] AOE Cannizzaro, Dept Pathol Anat, Via Messina,829, I-95126 Catania, Italy
[8] Univ Catania, Dept Med & Surg Sci & Adv Technol GF Ingrassia, Anat Pathol, Catania, Italy
[9] Santa Chiara Hosp, Unit Surg Pathol, APSS, Trento, Italy
关键词
Ovarian cancer; P53; BRCA; Homologous recombination repair; TCGA; TILs; PLATINUM-RESISTANT OVARIAN; FOLATE RECEPTOR-ALPHA; ANTITUMOR-ACTIVITY; DNA-REPAIR; PHASE-II; T-CELLS; CANCER; EXPRESSION; MUTATIONS; ANTIBODY;
D O I
10.1016/j.critrevonc.2024.104603
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
High-grade serous ovarian carcinoma (HGSOC) is the most aggressive subtype of epithelial ovarian cancer and a leading cause of mortality among gynecologic malignancies. This review aims to comprehensively analyze the morphological, immunohistochemical, and molecular features of HGSOC, highlighting its pathogenesis and identifying biomarkers with diagnostic, prognostic, and therapeutic significance. Special emphasis is placed on the role of tumor microenvironment (TME) and genomic instability in shaping the tumor's behavior and therapeutic vulnerabilities. Key advancements, such as the identification of TP53 and BRCA mutations, the classification of homologous recombination repair (HRR) deficiencies, and the clinical implications of biomarkers like folate receptor alpha (FR alpha) and PD-L1 are discussed. These findings reveal actionable insights into targeted therapies, including immune checkpoint inhibitors and PARP inhibitors, which hold promise for improving outcomes in HGSOC. This synthesis of knowledge aims to bridge gaps in understanding HGSOC's multifaceted biology, enhance clinical decision-making, and foster the development of precision therapies.
引用
收藏
页数:10
相关论文
共 50 条
  • [31] Tubal Precursor Lesions for High-Grade Serous Ovarian Carcinoma
    Meleis, Mahmoud Hanafy
    El-Agwany, Ahmed Mohammed Samy
    INDIAN JOURNAL OF GYNECOLOGIC ONCOLOGY, 2015, 13 (01)
  • [32] Tubo-Ovarian Transitional Cell Carcinoma and High-grade Serous Carcinoma Show Subtly Different Immunohistochemistry Profiles
    Magrill, Jamie
    Karnezis, Anthony N.
    Tessier-Cloutier, Basile
    Talhouk, Aline
    Kommoss, Stefan
    Cochrane, Dawn
    Chow, Christine
    Cheng, Angela
    Soslow, Robert
    Hauptmann, Steffen
    du Bois, Andreas
    Pfisterer, Jacobus
    Gilks, C. Blake
    Huntsman, David G.
    Kommoss, Friedrich
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 2019, 38 (06) : 552 - 561
  • [33] Development of Low-Grade Serous Ovarian Carcinoma from Benign Ovarian Serous Cystadenoma Cells
    Dey, Puja
    Nakayama, Kentaro
    Razia, Sultana
    Ishikawa, Masako
    Ishibashi, Tomoka
    Yamashita, Hitomi
    Kanno, Kosuke
    Sato, Seiya
    Kiyono, Tohru
    Kyo, Satoru
    CANCERS, 2022, 14 (06)
  • [34] The Fallopian tube odyssey: from the ovary to the tube. About high-grade serous ovarian carcinoma
    Chene, Gautier
    Dauplat, Jacques
    Radosevic-Robin, Nina
    Cayre, Anne
    Penault-Llorca, Frederique
    BULLETIN DU CANCER, 2013, 100 (7-8) : 757 - 764
  • [35] Tubal Precursor Lesions for High-Grade Serous Ovarian Carcinoma
    Mahmoud Hanafy Meleis
    Ahmed Mohammed Samy El-Agwany
    Indian Journal of Gynecologic Oncology, 2015, 13 (1)
  • [36] Outcomes of primary surgical cytoreduction in patients with BRCA-associated high-grade serous ovarian carcinoma
    Hyman, David M.
    Long, Kara C.
    Tanner, Edward J.
    Grisham, Rachel N.
    Arnold, Angela G.
    Bhatia, Jasmine
    Phillips, Mary F.
    Spriggs, David R.
    Soslow, Robert A.
    Kauff, Noah D.
    Levine, Douglas A.
    GYNECOLOGIC ONCOLOGY, 2012, 126 (02) : 224 - 228
  • [37] Most Commonly Mutated Genes in High-Grade Serous Ovarian Carcinoma Are Nonessential for Ovarian Surface Epithelial Stem Cell Transformation
    Yamulla, Robert Joseph
    Nalubola, Shreya
    Flesken-Nikitin, Andrea
    Nikitin, Alexander Yu
    Schimenti, John C.
    CELL REPORTS, 2020, 32 (09):
  • [38] Ovarian low-grade serous carcinoma: A comprehensive update
    Diaz-Padilla, Ivan
    Malpica, Anais L.
    Minig, Lucas
    Chiva, Luis M.
    Gershenson, David M.
    Gonzalez-Martin, Antonio
    GYNECOLOGIC ONCOLOGY, 2012, 126 (02) : 279 - 285
  • [39] Ovarian carcinoma: pathology review with an emphasis in their molecular characteristics
    Lino-Silva, Leonardo S.
    CHINESE CLINICAL ONCOLOGY, 2020, 9 (04)
  • [40] Morphological and Immunohistochemical Reevaluation of Tumors Initially Diagnosed as Ovarian Endometrioid Carcinoma With Emphasis on High-grade Tumors
    Lim, Diana
    Murali, Rajmohan
    Murray, Melissa P.
    Veras, Emanuela
    Park, Kay J.
    Soslow, Robert A.
    AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2016, 40 (03) : 302 - 312